Genetic Testing for TP53 Mutations (Li-Fraumeni Syndrome)

Last Review Date: November 9, 2018
Number: MG.MM.LA.35C3

Medical Guideline Disclaimer
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflect how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based on a review of currently available clinical information (including clinical outcomes studies in the peer-reviewed literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions
Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, cancer predisposition syndrome caused by germline mutations in the TP53 gene and associated with a high risk cancer occurrence. Commonly occurring cancers in LFS include osteosarcoma, premenopausal breast cancer, brain tumor, adrenocortical carcinomas and soft tissue sarcoma. TP53 genetic mutations are highly penetrant and individuals with LFS are predisposed to multiple primary tumors.

Related Medical Guideline
Genetic Counseling and Testing

Guideline
TP53 gene mutation testing is considered medically necessary when any of the following criteria are met:

1. Individual has a suspected or known clinical diagnosis of LFS or Li-Fraumeni-Like syndrome
2. Individual has a known family history of a TP53 mutation
3. Individual has a personal or family history for ALL of the following:
   a. Sarcoma diagnosed at < age 45 years
   b. First-degree relative diagnosed with cancer at < 45 years
   c. An additional first-or second degree relative, same lineage, diagnosed with cancer at < age 45 years, or sarcoma at any age
4. Individual diagnosed with breast cancer at ≤ age 35 years with negative BRCA1/BRCA2 test.
5. Individual diagnosed with a tumor from the LFS tumor spectrum (including osteosarcoma, leukemia, soft tissue sarcoma, adrenocortical carcinoma, brain tumor, breast cancer, lung bronchoalveolar cancer) at < age 46 years; and:
   a. Has at least one first-or second-degree relative with any of the above LFS spectrum tumors (other than breast cancer, if the proband has breast cancer) diagnosed at < age 56 years or with multiple primaries at any age
6. Individual diagnosed with multiple tumors (except multiple breast tumors), with the initial tumor diagnosed at < age 46 years and two tumors are from the LFS tumor spectrum, with the initial cancer occurring prior to age 46
7. Individual diagnosed with adrenocortical carcinoma, choroid plexus carcinoma, or embryonal rhabdomyosarcoma anaplastic subtype, at any age.
Limitations/Exclusions

1. TP53 gene mutation testing is considered investigational and not medically necessary for all indications that do not meet the above criteria.

2. TP53 gene mutation testing for LFS using panels of genes (with or without next generation sequencing) is considered investigational and not medically necessary when all components of a panel do not meet the above criteria.

References


Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81404</td>
<td>Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) (Revision eff. 01/01/2018)</td>
</tr>
<tr>
<td>81405</td>
<td>Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenic array analysis) CPOX (coproporphyrinogen oxidase) (eg, hereditary coproporphyria), full gene sequence CTRC (chymotrypsin C) (eg, hereditary pancreatitis), full gene sequence PKLR (pyruvate kinase, liver and RBC) (eg, pyruvate kinase deficiency), full gene sequence (Revision eff. 01/01/2018)</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>

Applicable ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C00.0–C96.9</td>
<td>Malignant neoplasms</td>
</tr>
<tr>
<td>Z15.01–Z15.09</td>
<td>Genetic susceptibility to malignant neoplasm</td>
</tr>
<tr>
<td>Z80.0–Z80.9</td>
<td>Family history of primary malignant neoplasm</td>
</tr>
<tr>
<td>Z85.00–Z85.9</td>
<td>Personal history of malignant neoplasm</td>
</tr>
</tbody>
</table>